Abbott gets USFDA nod for smallest implantable spinal cord stimulation system for chronic pain
Paired with Abbott's new Xtend energy technology, Eterna optimizes the patient charging experience, requiring as few as five recharges per year under standard use from a wireless charger.§
Abbott Park, Ill.: Abbott has announced the US Food and Drug Administration (USFDA) approval of the company's Eterna spinal cord stimulation (SCS) system – the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain.* Eterna SCS utilizes Abbott's proprietary low-dose BurstDR stimulation, which mimics natural firing patterns found in the brain to deliver superior** pain relief. BurstDR stimulation is preferred to traditional "tingling" tonic stimulation by 87% of patients.
Abbott developed Eterna based on extensive studies with patients, physicians and caregivers to understand the unmet needs of people living with chronic pain. Paired with Abbott's new Xtend energy technology, Eterna optimizes the patient charging experience, requiring as few as five recharges per year under standard use from a wireless charger.§ It uses Abbott's TotalScan MRI technology, which allows for full-body MRI scans – a critical need of chronic pain patients who require accessibility to improved diagnostics and healthcare. Abbott's patient-focused mobile app supports real-time battery life and charging status updates of the Eterna SCS system on a personal or Abbott-provided Apple device.
"Abbott's low-dose BurstDR stimulation is clinically proven to reduce pain, improve people's ability to perform everyday activities, and reduce emotional suffering associated with pain,"^ said Timothy Deer, M.D., DABPM, president and chief executive officer of the Spine and Nerve Centers of the Virginias in Charleston, W.Va. "Until now, it wasn't available on a rechargeable device that was this small, and that only needs to be charged a few times a year. This makes a big difference in comfort for many patients who now can have access to the best of both worlds – a small, best-in-class rechargeable device with superior stimulation therapy."
More than 50 million people in the U.S. suffer from chronic pain. According to the U.S. Pain Foundation, chronic pain is the leading cause of people going to the doctor and costs the nation approximately $635 billion each year in healthcare, disability, and lost productivity costs. SCS, also known as neurostimulation, has been recommended by doctors for more than 50 years to help people manage chronic pain and improve their quality of life. Devices used for SCS consist of thin wires placed between the spinal cord and the vertebrae and a small implant placed under the skin in the lower back that helps disrupt pain signals before they can reach the brain.
"At Abbott, we deliver products and solutions with the goal of simplifying healthcare, improving clinical outcomes and providing people suffering from chronic pain with the best experience possible. As we progress on this commitment, Eterna is the next major leap forward," said Pedro Malha, vice president, neuromodulation, Abbott. "Eterna is the smallest rechargeable spinal cord stimulator on the market, provides the longest therapy between charges and offers an optimized recharging experience – all key features when selecting the best overall system."*§
Abbott's portfolio of neuromodulation devices also includes Proclaim XR, the recharge-free SCS system, and Proclaim Plus featuring FlexBurst360, the SCS system that offers pain coverage across up to six areas of the trunk and/or limbs and enables programming that can be adjusted as a person's therapeutic needs evolve. All use the clinically proven low-dose BurstDR stimulation therapy.
